Skip to main
  1. Stocks
  2. Halozyme Therapeutics
  3. Forecast
HALO

Halozyme Therapeutics (HALO) Stock Forecast & Price Target

Halozyme Therapeutics (HALO) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 22%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Halozyme Therapeutics is supported by strong royalty revenue growth that beat estimates in both 2Q26 and 3Q26, with royalty revenue of $308MM and $341MM, respectively, and total revenue of about $481MM and ~$493MM. Its outlook is strengthened by broadening commercialization of ENHANZE-enabled products, including PHESGO, DARZALEX, VYVGART, OCREVUS, OPDIVO, and RYBREVANT, alongside rising subcutaneous conversion rates such as 59% for PHESGO and over 20% for OCREVUS, which expand the recurring royalty base. The company also has durable longer-term upside from 13 clinical-stage programs expected by YE2026, disciplined leverage reduction toward 1.1x by YE2026, and improving litigation leverage in Europe that could enhance future royalty streams and competitive positioning.

Bears say

Halozyme Therapeutics is exposed to a concentrated set of fundamental risks that weigh on the investment case, including technology, clinical, regulatory, commercial, and balance sheet uncertainty. Even though there have been no known safety issues with PH20 to date, any future safety signal could slow or halt commercialization, while partner candidates may fail in clinical trials or face FDA and other regulatory rejections that require additional studies. The company also faces intense competition if products reach market, and the high cost of drug development raises the risk that it may need to return to capital markets for additional financing.

Halozyme Therapeutics (HALO) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 22% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Halozyme Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Halozyme Therapeutics (HALO) Analyst Forecast & Price Prediction

Get the latest Halozyme Therapeutics (HALO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Halozyme Therapeutics (HALO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Halozyme Therapeutics (HALO) Forecast

Analysts have given Halozyme Therapeutics (HALO) a Buy based on their latest research and market trends.

According to 9 analysts, Halozyme Therapeutics (HALO) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Halozyme Therapeutics (HALO)


Halozyme Therapeutics (HALO) Analyst Forecast & Price Prediction

Get the latest Halozyme Therapeutics (HALO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Halozyme Therapeutics (HALO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HALO stock data and trends